Suppliers and packagers for oxbryta

oxbryta

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Global Blood Theraps	OXBRYTA	voxelotor	TABLET, FOR SUSPENSION;ORAL	216157	NDA	Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.	72786-111-02	60 TABLET, FOR SUSPENSION in 1 BOTTLE, PLASTIC (72786-111-02)	2021-12-17
Global Blood Theraps	OXBRYTA	voxelotor	TABLET, FOR SUSPENSION;ORAL	216157	NDA	Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.	72786-111-03	90 TABLET, FOR SUSPENSION in 1 BOTTLE, PLASTIC (72786-111-03)	2021-12-17
Global Blood Theraps	OXBRYTA	voxelotor	TABLET;ORAL	213137	NDA	Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.	72786-101-01	90 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72786-101-01)	2019-11-25
Global Blood Theraps	OXBRYTA	voxelotor	TABLET;ORAL	213137	NDA	Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.	72786-102-02	60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72786-102-02)	2019-11-25

OXBRYTA Supplier Landscape

Last updated: February 19, 2026

Who are the Key Suppliers for OXBRYTA?

The supply chain for OXBRYTA (voxelotor) involves several critical components, from active pharmaceutical ingredient (API) manufacturing to finished drug product formulation and packaging. Key suppliers are essential for ensuring the consistent availability of this medication, used to treat sickle cell disease.

API Manufacturing: The active pharmaceutical ingredient for OXBRYTA is voxelotor. This complex organic molecule requires specialized chemical synthesis. While the exact primary manufacturer of voxelotor is proprietary information held by Global Blood Therapeutics (GBT), now a subsidiary of Pfizer, contract manufacturing organizations (CMOs) often play a significant role in API production for pharmaceutical companies. These CMOs are selected based on their Good Manufacturing Practice (GMP) compliance, quality control systems, and capacity.

Formulation and Finished Drug Product: Once the voxelotor API is produced, it is formulated into the final dosage form, typically tablets. This process involves blending the API with excipients such as binders, fillers, disintegrants, and lubricants to create a stable and bioavailable product. The formulation and filling of OXBRYTA tablets are likely conducted by specialized pharmaceutical manufacturers, either in-house by Pfizer or through outsourced CMOs with expertise in solid dosage forms.

Packaging and Labeling: The final stage involves packaging the OXBRYTA tablets into bottles or blister packs, along with labeling that includes dosage information, warnings, and lot numbers. This step also adheres to strict regulatory requirements to ensure product integrity and patient safety. Packaging suppliers provide materials like high-density polyethylene (HDPE) bottles, induction seals, caps, and secondary cartons. Labeling suppliers provide the printed labels and patient information leaflets.

Key Considerations for Suppliers: Pharmaceutical suppliers for drugs like OXBRYTA must meet stringent regulatory standards set by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes:

• Quality Management Systems (QMS): Suppliers must have robust QMS in place, often compliant with ISO 9001 and specific pharmaceutical guidelines.
• Good Manufacturing Practices (GMP): All manufacturing and handling of pharmaceutical components must adhere to GMP regulations.
• Supply Chain Security: Measures to prevent counterfeiting and ensure the integrity of the supply chain are paramount.
• Regulatory Compliance: Suppliers must be prepared for inspections and audits by regulatory authorities and the drug manufacturer.
• Capacity and Reliability: The ability to consistently produce and deliver materials in the required volumes is critical to avoid drug shortages.

What are the Regulatory Requirements for Pharmaceutical Suppliers?

Suppliers for pharmaceutical products like OXBRYTA are subject to a comprehensive regulatory framework designed to ensure the quality, safety, and efficacy of the final drug product. These regulations are enforced by national and international health authorities.

United States: The U.S. Food and Drug Administration (FDA) is the primary regulatory body. Key regulations include:

• 21 CFR Part 210 and 211: Current Good Manufacturing Practice (CGMP) for Finished Pharmaceuticals. This covers all aspects of manufacturing, processing, packing, and holding of drugs.
• 21 CFR Part 11: Electronic Records; Electronic Signatures. Governs the use of electronic records and signatures in regulated activities.
• Supplier Qualification Programs: Drug manufacturers are responsible for qualifying their suppliers. This involves assessing the supplier's ability to consistently meet quality standards and regulatory requirements. Site audits, questionnaires, and review of quality agreements are common components.
• Drug Master Files (DMFs): API manufacturers often submit DMFs to the FDA. A DMF contains confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. Drug product manufacturers can then reference these DMFs in their drug applications.
• Quality Agreements: These are formal written agreements between a drug manufacturer and its supplier outlining specific responsibilities related to quality and regulatory compliance.

European Union: The European Medicines Agency (EMA) oversees regulatory affairs in the EU, with member states' national competent authorities also playing a role. Key requirements include:

• EudraLex Volume 4: Good Manufacturing Practice (GMP) Guidelines. This provides detailed guidance on GMP compliance for medicinal products.
• API Manufacturing: Manufacturers of APIs must comply with EU GMP guidelines. Certificates of GMP Compliance are issued after successful inspections.
• Supplier Audits and Qualification: Similar to the US, pharmaceutical companies must ensure their suppliers meet quality and regulatory standards through audits and qualification processes.
• ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides globally recognized guidelines that are adopted by regulatory bodies like the FDA and EMA. Relevant ICH guidelines include Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients) and Q10 (Pharmaceutical Quality System).

Other Global Requirements: Suppliers operating internationally must also be aware of the regulations in other major markets, such as those of Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and Health Canada. These often align with ICH guidelines.

Key Regulatory Aspects for OXBRYTA Suppliers:

• Traceability: Suppliers must be able to trace all materials used and products supplied.
• Change Control: Any changes to manufacturing processes, specifications, or facilities must be managed through a formal change control system and communicated to the drug manufacturer.
• Handling of Deviations and Complaints: Robust procedures for investigating deviations from specifications and handling customer complaints are required.
• Data Integrity: Ensuring the accuracy, completeness, and reliability of all generated data is a critical regulatory focus.

What are the Key Excipients Used in OXBRYTA Tablets?

Excipients are inactive substances used as carriers for the active ingredient (voxelotor) in pharmaceutical formulations. They play crucial roles in drug delivery, stability, manufacturing, and patient acceptance. The specific excipients used in OXBRYTA tablets are proprietary information of Pfizer, but based on the typical formulation of oral solid dosage forms, a standard set of excipients can be inferred.

The formulation of OXBRYTA (voxelotor) tablets, a.k.a. Voxelotor Tablets, must consider factors such as API solubility, stability, and desired release profile. Common excipient categories and potential candidates for OXBRYTA include:

1. Diluents/Fillers: These are added to increase the bulk of the tablet, making it large enough to handle and administer.

• Microcrystalline Cellulose (MCC): A widely used filler and binder, known for its compressibility and flow properties.
• Lactose Monohydrate: Another common filler, though its use can be limited in lactose-intolerant populations.
• Dibasic Calcium Phosphate: Often used as a filler and binder, particularly in direct compression formulations.

2. Binders: These substances hold the powdered ingredients together, forming granules that improve flowability and tablet compressibility.

• Povidone (Polyvinylpyrrolidone - PVP): A versatile binder used in various granulation processes.
• Hydroxypropyl Cellulose (HPC): A common binder offering good film-forming properties.
• Pregelatinized Starch: Used as both a binder and disintegrant.

3. Disintegrants: These agents facilitate the breakup of the tablet into smaller fragments after administration, promoting drug dissolution and absorption.

• Croscarmellose Sodium: A superdisintegrant that swells rapidly when exposed to water, accelerating tablet disintegration.
• Sodium Starch Glycolate: Another effective superdisintegrant, commonly used in tablet formulations.
• Crospovidone: A cross-linked polymer that swells and dissolves rapidly, aiding disintegration.

4. Lubricants: These are added to prevent the tablet formulation from sticking to the punches and dies of the tablet press during manufacturing.

• Magnesium Stearate: The most common lubricant, used at low concentrations.
• Stearic Acid: Can also be used as a lubricant.

5. Glidants: These improve the flowability of the powder mixture, ensuring consistent die filling and tablet weight.

• Colloidal Silicon Dioxide (Aerosil): A common glidant that reduces inter-particle friction.

6. Coating Agents: Tablets are often coated to improve palatability, mask odors, protect the API from light or moisture, aid in swallowing, or control drug release.

• Hypromellose (HPMC): A common film-forming agent used in tablet coatings.
• Titanium Dioxide: Used as an opacifier and white pigment in coatings.
• Polyethylene Glycol (PEG): Used as a plasticizer in film coatings.
• Iron Oxides (e.g., Red Iron Oxide): Used for coloration.

Example Formulation (Hypothetical based on common practice):

A hypothetical formulation for a 100 mg voxelotor tablet might include:

• Active Ingredient: Voxelotor (100 mg)
• Diluent: Microcrystalline Cellulose (e.g., 150 mg)
• Binder: Povidone (e.g., 10 mg)
• Disintegrant: Croscarmellose Sodium (e.g., 15 mg)
• Lubricant: Magnesium Stearate (e.g., 2 mg)
• Glidant: Colloidal Silicon Dioxide (e.g., 3 mg)

These components would be blended, granulated (if wet granulation is used), dried, milled, blended with lubricants and glidants, and then compressed into tablets. Subsequently, the tablets would be coated.

Supplier Considerations for Excipients: Companies manufacturing excipients for pharmaceutical use must also adhere to strict quality standards, including GMP, and often provide extensive documentation regarding their manufacturing processes, quality control, and regulatory compliance. Suppliers must ensure lot-to-lot consistency and provide certificates of analysis with each shipment.

What is the Market Landscape for Sickle Cell Disease Treatments?

The market for sickle cell disease (SCD) treatments is evolving, driven by an increased understanding of the disease's pathophysiology and the development of novel therapeutic agents. OXBRYTA, as a first-in-class therapy aimed at increasing hemoglobin A (HbA) levels, represents a significant advancement in managing SCD.

Key Treatment Modalities:

1. Supportive Care: This remains a cornerstone of SCD management, addressing complications and improving quality of life. It includes:

   • Pain Management: Analgesics, including opioids and non-opioids.
   • Blood Transfusions: To prevent stroke and manage severe anemia.
   • Hydroxyurea: The first disease-modifying therapy approved for SCD, it increases fetal hemoglobin (HbF) and reduces the frequency of pain crises.
   • Infection Prophylaxis: Antibiotics and vaccinations.

2. Disease-Modifying Therapies: These aim to address the underlying pathology of SCD.

   • OXBRYTA (Voxelotor): Approved to increase hemoglobin A (HbA) levels, thereby reducing the risk of vaso-occlusive events (VOEs) and anemia in patients with SCD. It targets the abnormal hemoglobin S (HbS) polymerization.
   • LUPKYNIS (Emapalumab): While primarily for hemophagocytic lymphohistiocytosis (HLH), its mechanism of targeting inflammatory pathways has led to research in SCD complications.
   • Givosiran: Approved for acute hepatic porphyria, its mechanism of targeting RNA can be relevant for certain SCD-related pathways.
   • Mitapivat: An allosteric activator of pyruvate kinase, it can improve red blood cell metabolism and reduce hemolysis. Approved for pyruvate kinase deficiency anemia and is in trials for SCD.

3. Curative Therapies: These offer the potential for a one-time cure.

   • Hematopoietic Stem Cell Transplantation (HSCT): The only curative option currently widely available, but limited by donor availability, transplant-related risks, and costs.
   • Gene Therapies: A rapidly advancing area. Several gene therapies are in clinical development, including those that aim to:
     • Increase fetal hemoglobin production (e.g., using lentiviral vectors).
     • Edit the sickle cell gene directly (e.g., using CRISPR-Cas9 technology).
     • Replace the defective beta-globin gene.
     • Examples include therapies developed by bluebird bio (e.g., ZYNTEGLO, now part of Pfizer's portfolio, though not directly related to OXBRYTA's mechanism) and Vertex Pharmaceuticals.

Competitive Landscape for OXBRYTA:

• Hydroxyurea: Remains a significant competitor due to its long-standing availability and established safety profile, although its mechanism differs from voxelotor.
• Other HbF Inducers: Research into other agents that increase fetal hemoglobin may offer alternative approaches.
• Agents Targeting Hemolysis: Therapies that reduce red blood cell destruction are also being developed and could compete with voxelotor's approach of improving oxygen carrying capacity.
• Gene Therapies: These represent the future of SCD treatment and, if successful and accessible, could significantly alter the market landscape by offering a cure.

Market Drivers:

• Growing Awareness and Diagnosis: Improved diagnostic capabilities and increased focus on SCD are expanding the patient population eligible for treatment.
• Unmet Medical Need: The debilitating nature of SCD and its associated complications create a strong demand for effective therapies.
• Advancements in R&D: Significant investment in SCD research is yielding promising new drug candidates.
• Regulatory Support: Expedited pathways for orphan drugs and rare diseases can accelerate market entry.

Challenges:

• Cost of Novel Therapies: Gene therapies and other advanced treatments are expected to be very expensive, posing significant access and reimbursement challenges.
• Disease Complexity: SCD is a multi-systemic disease with diverse manifestations, requiring tailored treatment approaches.
• Patient Adherence: Ensuring long-term adherence to chronic therapies can be difficult.

The market for SCD treatments is projected to grow substantially, with OXBRYTA playing a key role in the current landscape of disease-modifying therapies. However, the emergence of curative gene therapies presents a long-term competitive threat and a potential paradigm shift in SCD care.

What are the Potential Supply Chain Risks for OXBRYTA?

The supply chain for a complex pharmaceutical like OXBRYTA is vulnerable to various risks that can impact availability, cost, and quality. Proactive risk management is essential for ensuring continuous patient access.

1. API Manufacturing Disruptions:

• Reliance on Specialized CMOs: If the API (voxelotor) is manufactured by a limited number of specialized CMOs, any disruption at these facilities (e.g., equipment failure, quality issues, regulatory non-compliance, natural disasters) can halt production.
• Raw Material Shortages: The synthesis of voxelotor involves multiple chemical steps. Shortages or quality issues with any precursor chemicals or reagents can lead to API production delays.
• Geopolitical Instability: If critical raw materials or manufacturing sites are located in politically unstable regions, supply can be jeopardized by conflicts or trade restrictions.

2. Formulation and Finished Product Manufacturing Issues:

• Single-Source Excipients: If a critical excipient is sourced from a single supplier, any issue with that supplier (e.g., production problems, quality recall, financial instability) can impact the finished drug product.
• Capacity Constraints: For high-demand drugs, the manufacturing capacity for formulation, filling, and packaging may become a bottleneck.
• Quality Control Failures: Issues identified during batch release testing or post-market surveillance can lead to batch rejections or recalls, impacting supply.

3. Logistics and Distribution Challenges:

• Transportation Disruptions: Weather events, port congestion, labor strikes, or fuel shortages can delay the shipment of raw materials, finished products, and their delivery to wholesalers and pharmacies.
• Cold Chain Requirements: While OXBRYTA is a solid oral dosage form and typically does not require strict cold chain, any specific handling or temperature sensitivities during transit could introduce risks.
• Customs and Import/Export Regulations: Changes in trade policies or customs procedures can create delays and increase costs for international supply chains.

4. Regulatory and Compliance Risks:

• GMP Non-Compliance: Inspections by regulatory authorities (e.g., FDA, EMA) can reveal non-compliance issues, leading to warning letters, production shutdowns, or import bans.
• Changes in Regulations: Evolving regulatory requirements for manufacturing, quality, or labeling can necessitate costly changes to processes and systems, potentially disrupting supply.
• Data Integrity Issues: Failures in data integrity systems or practices at any stage of the supply chain can lead to significant regulatory scrutiny and supply interruptions.

5. Counterfeiting and Diversion:

• Substandard or Falsified Medicines: The complexity of pharmaceutical supply chains can create opportunities for counterfeit products to enter the market, posing a serious risk to patient safety.
• Diversion: Legitimate products being diverted to unauthorized markets can disrupt intended distribution channels and create shortages.

Mitigation Strategies:

• Dual Sourcing: Qualifying multiple suppliers for critical raw materials, APIs, and excipients to reduce reliance on a single source.
• Robust Quality Agreements: Establishing clear quality expectations and responsibilities with all supply chain partners.
• Inventory Management: Maintaining adequate safety stock of raw materials, intermediates, and finished products to buffer against short-term disruptions.
• Supply Chain Visibility: Implementing technologies to track materials and products throughout the supply chain, enabling faster identification and response to issues.
• Contingency Planning: Developing detailed contingency plans for various disruption scenarios, including alternative manufacturing sites and logistics providers.
• Regular Audits and Assessments: Conducting frequent audits of suppliers to ensure ongoing compliance with quality and regulatory standards.
• Security Measures: Implementing robust security protocols to prevent counterfeiting and diversion.

Key Takeaways

• The supply chain for OXBRYTA involves specialized API manufacturing, formulation, and packaging, relying on a network of qualified suppliers.
• Suppliers must adhere to stringent Good Manufacturing Practice (GMP) regulations and quality management systems enforced by bodies like the FDA and EMA.
• Common excipients for oral solid dosage forms like OXBRYTA include diluents, binders, disintegrants, lubricants, glidants, and coating agents, each sourced from compliant suppliers.
• The sickle cell disease market is characterized by a mix of supportive care, disease-modifying therapies like OXBRYTA, and emerging curative gene therapies, creating a dynamic competitive landscape.
• Potential supply chain risks include API manufacturing disruptions, formulation issues, logistics challenges, regulatory non-compliance, and counterfeiting, necessitating robust risk mitigation strategies such as dual sourcing and contingency planning.

Frequently Asked Questions

1. Who is the primary manufacturer of the voxelotor API? The primary manufacturer of the voxelotor API is proprietary information held by Pfizer, the parent company of Global Blood Therapeutics. It is likely produced by a specialized contract manufacturing organization (CMO) compliant with pharmaceutical manufacturing standards.

2. Are there any government subsidies or incentives for OXBRYTA suppliers? While specific subsidies for OXBRYTA suppliers are not publicly disclosed, the development of treatments for rare diseases like sickle cell disease often benefits from government incentives such as orphan drug designations, tax credits, and fee waivers, which can indirectly encourage robust supply chain development.

3. What is the typical lead time for sourcing specialized pharmaceutical excipients? Lead times for specialized pharmaceutical excipients can vary significantly, typically ranging from 4 to 12 weeks, depending on the excipient's complexity, supplier inventory, and custom manufacturing requirements.

4. How does Pfizer ensure the quality and reliability of its OXBRYTA suppliers? Pfizer employs a rigorous supplier qualification program that includes comprehensive site audits, quality agreement establishment, batch testing verification, and ongoing performance monitoring to ensure consistent quality and regulatory compliance.

5. What is the projected market size for sickle cell disease treatments in the next five years? Market research reports project significant growth in the sickle cell disease treatment market, with estimates ranging from USD 7 billion to over USD 15 billion within the next five years, driven by new drug approvals and expanded access to innovative therapies.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) for Finished Pharmaceuticals. Retrieved from [FDA Website] (Specific URL not provided as it is a general regulatory area). [2] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union Volume 4 - Good Manufacturing Practice (GMP) Guidelines. Retrieved from [EMA Website] (Specific URL not provided as it is a general regulatory area). [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1998). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7. Retrieved from [ICH Website] (Specific URL not provided as it is a general regulatory area). [4] Global Blood Therapeutics. (2019). Branded Prescription Drug Data. OXBRYTA® (voxelotor) tablets. Retrieved from [Company Product Information] (Specific URL not provided as it is product-specific data). [5] Pfizer Inc. (2023). Annual Report on Form 10-K. Retrieved from [SEC EDGAR Database] (Specific URL not provided as it is a general financial filing). [6] Various Market Research Reports on Sickle Cell Disease Market. (Dates vary). Published by firms such as Grand View Research, Allied Market Research, etc. (Specific reports and URLs not provided as they are proprietary and date-dependent).